Eli Lilly and Company (NYSE:LLY - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 20.780-22.280 for the period, compared to the consensus EPS estimate of 22.400. The company issued revenue guidance of $58.0 billion-$61.0 billion, compared to the consensus revenue estimate of $59.6 billion.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the company. HSBC cut Eli Lilly and Company from a "buy" rating to a "reduce" rating and cut their target price for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Truist Financial lifted their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Finally, Cantor Fitzgerald started coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $1,002.80.
Get Our Latest Stock Report on Eli Lilly and Company
Eli Lilly and Company Stock Performance
NYSE:LLY traded down $1.96 during trading on Monday, reaching $821.66. The company's stock had a trading volume of 2,887,418 shares, compared to its average volume of 3,475,234. The firm has a market cap of $779.07 billion, a price-to-earnings ratio of 70.17, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm has a 50 day moving average of $825.36 and a 200-day moving average of $814.96.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. During the same period last year, the business posted $2.58 earnings per share. The firm's quarterly revenue was up 45.2% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.73%. Eli Lilly and Company's dividend payout ratio (DPR) is currently 51.24%.
Insider Transactions at Eli Lilly and Company
In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.13% of the company's stock.
Institutional Trading of Eli Lilly and Company
An institutional investor recently raised its position in Eli Lilly and Company stock. Brighton Jones LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 22.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 9,597 shares of the company's stock after purchasing an additional 1,730 shares during the quarter. Brighton Jones LLC's holdings in Eli Lilly and Company were worth $7,409,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.
Eli Lilly and Company Company Profile
(
Get Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
